ADA and rheumatoid arthritis: Compared to this early RA cohort, a lower proportion of the cross-sectional cohort, or 14% (37 of 270 patients) of the whole cohort were found to be ADA positive in samples with sIFX levels <0.2 μg/mL (42 of 270), probably reflecting a selection bias of patients who continue on infliximab.